DNA Damage and Repair 1

• 230 · PDF AZD4956, a potent and selective inhibitor of DNA polymerase theta, enhances the activity of DNA-damaging agents in HRR defective cellular backgrounds and improves efficacy of the new generation PARP1-selective inhibitor, saruparib Josep V. Forment, Lee Mulderrig, Christelle de Renty, Harriet Southgate, Gemma Jones, Martina Gesu, Rebecca Sargeant, Daniel Sutton, Lenka Oplustil O'Connor, Susan Critchlow, Sabina Cosulich
• 231 Polymerase iota drives aberrant mitotic DNA synthesis and replication stress in BRCA2 deficient human mammary epithelial cells Kavya Vipparthi, Ariana Bellare, Resul Ozbilgic, Mihriban Karaayvaz
• 232 · PDF IDE034, A bispecific antibody-drug conjugate co-targeting PTK7 and B7-H3, exhibits avidity-driven selectivity and enhanced antitumor activity versus mono-specific ADCs Diana M Munoz Delgado, Ying Zhu, Yanan Guo, Yuelei Shen, Peiran Li, Reeja Maskey, Pei Xin Lim, Megan Conway, Marcus M. Fischer, Vidhya Nagarajan, Arjun A. Rao, Christian Frey, Yuchen Bai, Paul A. Barsanti, Claire Neilan, Mike A. White
• 233 · PDF Preclinical development of EIK1005, a potent and selective inhibitor of Werner helicase Fernando Rodriguez Perez, Danny Murnock, Juanita Ezemba, Tamer Ahmed, Jose Ortega, Huntly M. Morrison, Rafael Miranda, Taylor Heuer, Stephen Jones, Brenda Smith, Ali Tabatabaei, Stephen Basham, Melissa Dumble, Marcus P. Kelly
• 234 · PDF Proteomic profiling of FEN1 inhibition by BSM-1516 reveals chromatin-associated biomarkers for preclinical pharmacodynamic evaluation Jason Munguia, Sanjay Agarwalla, Dave Martin, Junhua Fan, Jack Schultz, Celeste Giansanti, David Cortez, David Puerta, Zachary Zimmerman, Konstantin Taganov
• 235 · PDF Cellular comparison of a covalent and non-covalent WRN inhibitor reveals shared and unique response biomarkers Gerarda van de Kamp, Daphne J. F. Kluitmans, Tsang W. Lam, Jeroen A. D. M. de Roos, Janneke J. T. M. Melis, Jeffrey J. Kooijman, Jorg C. J. Benningshof
• 236 · PDF Targeting DNA damage sensors (DDS) to enhance Osimertinib response in EGFR-driven cancers Pamela L. Mendoza-Munoz, Madison E. Gerbig, John J. Turchi, Shadia I. Jalal
• 237 · PDF Selective Cytotoxicity of Base Excision Repair Inhibitor, TRC102, in DNA Damage Response Hyperactivated Glioblastoma Shaunak Sathe, Qi Li, Jinkyu Jung, Peng Lu, Zach Sergi, Herui Wang, Jing Wu
• 238 · PDF Targeted degradation of DNA ligase IV through a double-stranded DNA-based PROTAC for precision radiosensitization Monica Pandey, Daniel S Higginson
• 239 · PDF Potent synergy between CHK1/2 inhibitor ACR-368 and the ADC payload topoisomerase I inhibitor: Rationale for ADC + ACR-368 combination therapy Portia Lombardo, Ahmed Youssef, Mohamed Eldeeb, Nina Lipjankic, Martina Pasetto, Ruban Cornelius, Sofija Skoric, Ignacio Arribas Diez, Zachary Best, Anna-Maria Alves, Subodh Kumar, Kate Rappard, Calvin Yang, Corey Xu, Emma Ahrman, Valentina Siino, Taronish Dubash, Joelle Baddour-Sousounis, Reina Improgo, Magnus E. Jakobsson, Ayesha Murshid, Helén Åsa Nilsson, Lei Shi, Caroline Maria Wigerup, Michail Shipitsin, Joon Jung, David Proia, Erick Gamelin, Mansoor Mirza, Kristina Masson, Peter Blume-Jensen
• 240 Allele-specific sensitization of pancreatic ductal adenocarcinoma to PARP inhibition via adenine base editing Jin Zhang, Jingrui Yan, Tianxing Zhou, Xiuchao Wang, Chao Yang, Jun Yu, Jihui Hao
• 241 · PDF Targeted drug screening identifies novel compounds enabling accelerated mismatch repair deficiency (MMRd) for immunotherapy sensitization Benoit Rousseau, Miteshkumar Patel, Karthik Rangavajhula, Lin Zhang, David Mieles, James R. White, Oliver Artz, Shrey Patel, Somer Abdelfattah, Neil Segal, Luis A. Diaz
• 242 · PDF Targeting the DNA damage response sensor replication protein A for first in class cancer therapy Pamela VanderVere-Carozza, Matthew R. Jordan, Katherine Pawelczak, John J. Turchi
• 243 · PDF DNA fiber-based replication phenotypes distinguish WEE1-inhibitor response in high-grade endometrial cancer patient-derived organoids (PDOs) treated with azenosertib Elena Ivanova, Ke Cong, Shrabasti Roychoudhury, David Han, Magdalena Zielinska, Minh Ha, Abrielle Jens, Vaishnavi Anand, Bose S. Kochupurakkal, Courtney H. Qi, Arunika Shee, Maureen Mulready, Madison Zizzo, Alexis Rabbitt, Jennifer D. Curtis, Nabihah Tayob, Marisa R. Nucci, Cam A. Tran, Panagiotis A. Konstantinopoulos, Geoffrey I. Shapiro, Dipanjan Chowdhury, Cloud P. Paweletz, Ursula Matulonis, Joyce Liu
• 244 · PDF DHX9 inhibition is synthetically lethal with homologous recombination deficient and dMMR/MSI-H cancers and synergizes with PARP1 inhibition and chemotherapy Samantha S. Hodge, Natalie Hill, Jhansi L. Leslie, Umida Djakbrova, Logan Chinn, Saranya Chandrasekar, Susan Paprcka, Ester Fernández-Salas
• 245 · PDF Expanding the therapeutic window of PARP inhibitors by co-administering PARG inhibitors Giacomo G. Rossetti, Michalis Petropoulos, Theodoros Rampias, Thanos D. Halazonetis
• 246 · PDF Discovery and mechanistic characterisation of the first oral bioavailable FEN1 inhibitor for treatment of HRD and EWS cancers and combination with various DDR inhibitors Lars T. Burgdorf, Julien Lefranc, Lucy Armstrong, Roch Boivin, Joerg Bomke, Xiaoling Chen, Paula Costales, Owen A. Davis, Lizbeth DeSelm, Elias Elinati, Maria Filipa Pinto, Bruce Follows, Alessandro Galbiati, Catherine Jorand-Lebrun, Timothea Konstantinou, Julian Kreis, Claudio A. Lademann, Birgitta Leuthner, Jayesh B. Majithiya, Balca R. Mardin, Bethany Mason, Claire L. McWhirter, Djordje Musil, Ulrich Pehl, David Perera, Silvia Peripolli, Carl Petersson, Eeson Rajendra, Christin Rakers, Ada Sala-Hojman, Graeme C. M. Smith, Fiona Sorrell, Ana Toste Rêgo, Helen M. R. Robinson, Frank T. Zenke, Robert A. Heald, Sam E. Mann
• 247 · PDF Multiomic and preclinical assessment of ATR and Aurora kinase inhibitors in diverse TNBC models Nathan M. Merrill, Hamadi Madhi, Nathalie M. Vandecan, Athena Marie Apfel, Habib Serhan, Peter J. Ulintz, Liwei Bao, Aki Morikawa, Matthew B. Soellner, Soffia D. Merajver
• 248 · PDF Nesuparib (JPI-547), a dual tankyrase/PARP inhibitor, exhibits potent antitumor activity in small-cell lung cancer models by modulating Wnt and Hippo signaling pathways Jun Kim, Joon-Hyung Lee, John Kim, Hyunju Cha, Seounghun Kang
• 249 · PDF MOMA-313, an inhibitor of the DNA polymerase theta helicase domain, prevents BRCA reversions in preclinical models Giulia Bottoni, Anthony Tubbs, Kelly McGlynn, Vinny Motwani, Michael Reutershan, Timothy Guzi, Erica Evans, Peter Hammerman, Jordan A. Krall
• 250 · PDF Targeting DNA damage repair pathway and CCR2⁺ myeloid cell to overcome radioimmunotherapy resistance in small cell lung cancer Zhuoran Yao, Hui Wang, Kai Kang, Min Yu, Feifei Na, Ren Luo, Linglu Yi, Ruizhan Tong, Jianxin Xue, You Lu
• 251 · PDF Targeting cyclin K-CDK12 synergizes with ATR inhibition by limiting RPA chromatin loading in triple-negative breast cancer Eun-Bee Choi, Sophia Podeszwa, Ah-Ram Kim, Ashwani Bahl, Geoffrey I. Shapiro
• 252 · PDF Targeting replication stress promotes immunogenic cell death in chordoma Nindo Punturi, Arijit Ghosh, Caitlin King, Wendy Leung, Joan B. Levy, Lee Zou, Gregory M. Cote, Dan Freed
• 253 · PDF Antitumor activity of PARP inhibitors in combination with Temozolomide in fumarate hydratase-deficient RCC Sameer Issaq, Kylie Enten, Emily Hnath, Komal Rawal, Ramaprasad Srinivasan
• 254 · PDF The PARP1-selective inhibitor and trapper saruparib achieves extended PARP1 target engagement in vitro , in vivo and in the clinic Mark Robert Albertella, Giuditta Illuzzi, Anna D. Staniszewska, Domenic Pilger, Sophie Cooke, Spiros Linardopoulos, Anna Beckett, Christopher Stubbs, Ganesh Moorthy, Mark J. O'Connor

在完整检索应用中浏览本分会场 →